SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

Brain Research

Volumn 892, Issue 2, 2001, Pages 241-247

  Muralikrishnan, Dhanasekaran ^a   Ebadi, Manuchair ^a  

^a UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine receptor agonist; MPTP; Neurodegeneration; Neuroprotection; Oxidative stress; Parkinson's disease; Selegiline; SKF 38393

Indexed keywords

1 METHYL 4 PHENYL PYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; DRUG METABOLITE; GLUTATHIONE; SELEGILINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTIOXIDANTS; CATALASE; DOPAMINE AGENTS; DOPAMINE AGONISTS; GLUTATHIONE; MICE; MICE, INBRED BALB C; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEUROTOXICITY SYNDROMES; SELEGILINE; SUPEROXIDE DISMUTASE;

EID: 0035936962     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02994-2     Document Type: Article

References (47)

1. Catalase in vitro
2. Brain peroxidase and catalase in Parkinson's disease
3. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys
4. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
5. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man
6. Bromocriptine in parkinsonism
7. Metabolism of the neurotoxic tertiary amine by monoamine oxidase
8. A fluorometric assay for glutathione
9. Chronic parkinsonism secondary to intravenous injection of meperidine analogs
10. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat
11. Oxidative stress and antioxidant therapy in Parkinson's disease
12. Therapeutic potential of selegiline in Parkinson's disease and other neurological disorders
13. Glutathione and metallothionein in oxidative stress of Parkinson's disease
14. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset
15. Nitric oxide, mitochondria and neurological disease
16. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice
17. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
18. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatial dopamine in mice
19. Dopamine (3-hydroxytyramine) and brain function
20. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey
21. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin
22. Oxidative stress and the pathogenesis in Parkinson's disease
23. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
24. Involvement of superoxide anion radical in the autooxidation of pyrogallol and a convenient assay for superoxide dismutase
25. Experimental Parkinson's disease in monkeys: Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas
26. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
27. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Relationship with low levels of regional monoamine oxidase-B
28. Inhibition of mitochondrial respiration by1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo
29. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF-38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset
30. The D1 agonist SKF-38393 inhibits the antiparkinsonian activity of the D2 agonist LY-171555 in the MPTP-treated marmoset
31. Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
32. Etiology and pathogenesis of Parkinson's disease
33. Parkinson's disease: A disorder due to nigral glutathione deficiency?
34. Antiparkinsonian therapies and brain mitochondrial complex I activity
35. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism
36. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF-38393
37. 7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum
38. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra
39. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia
40. +), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
41. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family
42. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain
43. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria
44. Dopamine receptors and sensorimotor behavior in MPTP-treated mice
45. Suppression of hydroxyl radical formation and protection of nigral neurons by 1-deprenyl (selegiline)
46. The dopamine D1 receptor agonist SKF-38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
47. Neurochemical and neuroprotective effects of some aliphatic propargylamines: New selective non-amphetamine-like monoamine oxidase B inhibitors